The heterotrimeric guanine nucleotidebinding protein (G protein)-coupled receptor Smoothened (Smo) is the signaltransducing component of the Hedgehog (Hh) pathway, an essential driver of tissue morphogenesis that, when corrupted, contributes to cancer. Aberrant signaling is causative in basal cell carcinoma and medulloblastoma and is implicated in additional malignancies, including breast cancer (1) . Ectopic signaling is associated with mutation of select pathway regulatory components, but can also result from amplifi cation or ectopic expression of wild-type pathway effector genes. Consistent with the latter scenario, SMO is frequently overexpressed in both noninvasive ductal carcinoma in situ and invasive breast cancer. Ectopic Smo is proposed to contribute to breast cancer development through paracrine enhancement of cell proliferation, as has been documented for the oncogenic SmoM2 mutant (2) . The mechanism by which the constitutively active SmoM2 mutant signals to induce this paracrine response has not yet been reported and is the focus of the highlighted study (3) .
Genetic evidence in Drosophila supports that Smo signals through Gα i to modulate target gene expression (4) . Although vertebrate Smo is also documented to activate Gα i , its role in vertebrate signaling has remained controversial. Current models suggest that Gα i signaling downstream of Smo is dispensable for Gli-mediated Sonic Hh (Shh) target gene induction and instead initiates a distinct Gli-independent signal to infl uence cellular Ca 2+ fl ux, migration, metabolism, and proliferation (5, 6) . Although in vitro evidence supporting Smo-mediated Gα i signaling in such processes continues to mount, a genetic loss-of-function study in mouse linking Gα i with Smo has been lacking. In this issue, Villanueva and colleagues provide such evidence by revealing Gα i2 to be a requisite downstream effector of Smo in mammary epithelial cell (MEC) proliferation.
Smo signaling through Gα i has been implicated in the proliferation of cerebellar granular neuronal precursors (7) . To determine whether similar mechanisms might be in place in MECs, the authors used a Creinducible dual fl uorescent reporter system to conditionally express SmoM2 in cells marked by enhanced green fl uorescent protein (EGFP). Nonrecombined cells were marked by tdTomato, enabling identifi cation of SmoM2-expressing and -nonexpressing populations (Fig. 1 ). Using these mice, the authors tested the sensitivity of MEC proliferation to Gα i/o -inactivating pertussis toxin (PTX). They found that the overt proliferative response of tdTomato cells neighboring EGFP-positive SmoM2 cells was compromised by PTX treatment, suggesting involvement of a Gα i/o family protein. To rule out a general Gα i/o requirement for MEC proliferation, the authors examined whether PTX treatment would affect hormone-or pregnancy-induced proliferation. The response was unaltered in these contexts, suggesting that Gα was specifi cally involved in SmoM2-induced MEC proliferation.
To determine the specifi c 
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Lumen to hypothesize that it was the To identify candidate signals induced by SmoM2-Gα i2 signaling that might be responsible for triggering the paracrine response, the authors performed Ingenuity Pathway Analysis on RNA-seq data from SmoM2-expressing and -nonexpressing populations. This analysis revealed a gene expression association implicating axon guidance signaling. Genes involved in Slit/ Robo, Ephrin, Semaphorin-Plexin, and neurotrophic signaling showed increased expression in SmoM2-expressing cells. mRNAs encoding cognate receptors and ligands were coordinately induced in nonexpressing cells, suggesting the generation of circuits that may convey the proliferative signal between the two cell populations (Fig. 1) . The involvement of axon guidance pathways in cell adhesion and proliferation, and their frequent intersection with Ras-Raf-MAPK (mitogen-activated protein kinase) signaling, make them attractive candidates for driving the SmoM2-regulated proliferative response. Moreover, precedent exists for Gα involvement in regulation of Ephrin and Plexin family genes (8, 9) . However, these genes are typically induced through Gα s signaling and have not yet been documented to be induced by Gα i signaling.
Although various interesting candidate pathways were identifi ed, their involvement downstream of SmoM2 was not examined by Villanueva et al. and will be important topics for future research. The contribution of transcription-independent signaling should also be considered, because the dispensability of Gli activity in SmoM2-induced MEC proliferation suggests that the paracrine response may be directly activated by Gα i2 . Such a mechanism has been documented in cardiomyocytes and fi broblasts, in which receptor-mediated activation of Gα i transactivates proliferative epidermal growth factor receptor (EGFR) signaling through direct regulation of matrix metalloproteases (MMPs). This regulation occurs through Gβγ which, upon release from the activated Gα, stimulates MMP to cleave EGF ligands, facilitating their release for autocrine and paracrine receptor activation (10) . It will be informative to test whether similar transactivation mechanisms occur in SmoM2-expressing MECs.
The identifi cation of Gα i2 as a requisite effector of SmoM2-mediated MEC proliferation expands the repertoire of cellular processes controlled by Gli-independent Smo signaling. Pinpointing the precise mechanism by which SmoM2 and Gα i2 signal to induce paracrine responses, and determining their contribution to oncogenic pathway activity, are important open questions. The therapeutic relevance of answering them is underscored by the discovery that cyclopamine, a potent inhibitor of Smo-Gli signaling, behaves as a partial agonist for Smo-Gα i signal induction (6) . Characterizing the Smo-Gα i axis will therefore be an essential step toward improving targeted therapies, because smallmolecule Smo modulators may have differing effects on Gli and Gα i signal output.
